Department of Clinical and Experimental Pharmacology

Calcutta School Of Tropical Medicine

Dermatitis

Atopic Dermatitis

Eczema

Pneumococcal Infections

COVID-19

ASLAN004

Abrocitinib

S-217622

Pfizer

Aslan Pharmaceuticals

Shionogi

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India. AD, also known as atopic eczema, is a chronic, relapsing skin condition characterized by dry, itchy skin lesions which can affect any part of the body. Adult peoples who participate in this study will take either 100 mg or 200 mg of abrocitinib tablets by mouth for a duration of 12 weeks and adolescents will take for duration of 52 weeks. Knee Magnetic Resonance Imagine (MRI) will be done on adolescent peoples to determine bone safety findings. We will examine the experiences of people receiving the study medicines. This will help us determine if the study medicines are safe and how well they work.

A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

Calcutta School Of Tropical Medicine | Department of Clinical and Experimental Pharmacology

Site insights

Work at this site?

Active trials

A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

Trial sponsors